Welcome to InfiCure Bio
InfiCure Bio is a life science company focusing on preclinical development and validation of drugs that target chronic inflammatory and fibrotic conditions.
Based on a panel of in vivo models for these conditions including a proprietary model, the NIF mouse, for chronic inflammation and fibrosis, we offer effect tests of anti-inflammatory and anti-fibrotic drugs.
Founded on extensive experience and expertise in immunology, inflammation and fibrosis research, InfiCure Bio offers a proficient and flexible processing of drug validation projects in this area.
News
Pressrelease: InnoSer and Inficure Bio enter partnership
InnoSer and Inficure Bio enter partnership to increase accessibility of translational liver inflammation & fibrosis mouse model Read the entire pressrelease here!
Pressrelease: InfiCure Bio signs agreement with two major international companies
The Umeå based life science company InfiCure Bio continues to take large steps in the global market by signing agreements with two major international companies. “The contracts with our new clients clearly show that pharmaceutical [...]
NLSDays September 28-29
Sofia Mayans, CEO at Inficure Bio, will attend the annual Nordic Life Science Days in Malmö 28-29 September. We hope that you will meet Sofia in Malmö for fruitful discussions!
InfiCures attended with poster at the EASL NAFLD summit Sept 15-17!
InfiCure attended the EASL NAFLD summit digitally, please take the opportunity to read our poster "Effects of high fat diet on development of NASH in the NIF mouse model". The poster can be found here.